Genzyme's FDA issues remain unresolved

Genzyme suffered a surprising regulatory setback in plans to expand production of its treatment for Pompe disease, after the company had issued an optimistic outlook based in part on its prediction that the expansion would be cleared. Report

Suggested Articles

Compared with the FDA "boxed warning," the EMA version puts a smaller restriction on the higher dose but broadens the cautionary language.

Shionogi's newest antibiotic Fetroja has now earned the FDA's approval, but will a mortality-rate warning scuttle the drug's chances?

Novartis' Sandoz doubled down in Japan as Lupin retreated. Dr. Reddy's posted a loss tied to its Zantac recall. Aslan's varlitinib failed again.